Regeneron Pharmaceuticals (REGN)

Jan 17, 2025, 11:00 AM EST - 14 hours ago

Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 16, 2025, 9:15 AM EST - 1 day ago

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.

Jan 15, 2025, 10:34 AM EST - 2 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Jan 15, 2025, 10:15 AM EST - 2 days ago

Regeneron Pharmaceuticals Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 15, 2025, 8:30 AM EST - 2 days ago

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 14, 2025, 7:52 PM EST - 3 days ago

Long-term possibilities in healthcare are unbelievable, says Jim Cramer

ABT CAH LLY MRK

Jan 14, 2025, 7:16 PM EST - 3 days ago

Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights

Jan 14, 2025, 6:57 PM EST - 3 days ago

Jim Cramer says he supports healthcare stocks for their long-term value

LLY MRK

Jan 14, 2025, 12:00 PM EST - 3 days ago

Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith

Jan 14, 2025, 10:45 AM EST - 3 days ago

Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Should Contact the Shareholders Foundation in Connection With Lawsuit

Jan 13, 2025, 7:08 PM EST - 4 days ago

Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 13, 2025, 11:15 AM EST - 4 days ago

Regeneron Pharmaceuticals Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 13, 2025, 6:30 AM EST - 4 days ago

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 6:15 AM EST - 4 days ago

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

Jan 13, 2025, 6:07 AM EST - 4 days ago

Truveta sells stakes to Regeneron, Illumina in deal to build genetic database

ILMN

Jan 13, 2025, 6:05 AM EST - 4 days ago

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

Jan 13, 2025, 5:45 AM EST - 4 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

Jan 11, 2025, 11:45 AM EST - 6 days ago

Regeneron Pharmaceuticals Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Jan 10, 2025, 11:15 AM EST - 7 days ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.

Jan 7, 2025, 4:05 PM EST - 10 days ago

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

Jan 5, 2025, 10:00 AM EST - 12 days ago

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Dec 19, 2024, 7:00 AM EST - 4 weeks ago

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Dec 17, 2024, 4:05 PM EST - 4 weeks ago

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 4:30 PM EST - 4 weeks ago

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

Dec 9, 2024, 5:45 PM EST - 5 weeks ago

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

Dec 7, 2024, 7:00 PM EST - 5 weeks ago

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Dec 5, 2024, 2:55 PM EST - 6 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)

Dec 4, 2024, 1:00 PM EST - 6 weeks ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Dec 3, 2024, 5:00 AM EST - 6 weeks ago

Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.

Dec 2, 2024, 12:00 PM EST - 6 weeks ago

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Nov 19, 2024, 4:09 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)